Peter Ellinghaus
Merck (Germany)(DE)
Publications by Year
Research Areas
Cancer, Hypoxia, and Metabolism, Fibroblast Growth Factor Research, Medical Imaging Techniques and Applications, Bladder and Urothelial Cancer Treatments, Eosinophilic Disorders and Syndromes
Most-Cited Works
- → Defective peroxisomal catabolism of branched fatty acyl coenzyme A in mice lacking the sterol carrier protein-2/sterol carrier protein-x gene function(1998)263 cited
- → Novel Aspects of Fibrin(ogen) Fragments during Inflammation(2011)245 cited
- → What makes a good drug target?(2011)242 cited
- → BAY 87‐2243, a highly potent and selective inhibitor of hypoxia‐induced gene activation has antitumor activities by inhibition of mitochondrial complex I(2013)223 cited
- → Phytanic Acid Activates the Peroxisome Proliferator-activated Receptor α (PPARα) in Sterol Carrier Protein 2-/ Sterol Carrier Protein x-deficient Mice(1999)172 cited
- → Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study(2019)170 cited
- → Mimicking Hypoxia to Treat Anemia: HIF-Stabilizer BAY 85-3934 (Molidustat) Stimulates Erythropoietin Production without Hypertensive Effects(2014)170 cited
- → Overexpression of PH-4, a novel putative proline 4-hydroxylase, modulates activity of hypoxia-inducible transcription factors(2002)164 cited
- → Plasma Biomarkers of Myocardial Fibrosis and Remodeling in Terminal Heart Failure Patients Supported by Mechanical Circulatory Support Devices(2008)158 cited
- → Combined Tyrosine and Serine/Threonine Kinase Inhibition by Sorafenib Prevents Progression of Experimental Pulmonary Hypertension and Myocardial Remodeling(2008)154 cited